What failed BIA 10–2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials

ABSTRACT

It is now known through the various studies that the endocannabinoids have dual role in human health. On the one hand, they contribute to the etiology of some diseases; on other they play “protective role” in some other disease states. This evoked the interest in developing exogenous drugs that can modulate cannabinoid system.

KEYWORDS

• Commentary

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.4103/0976-500X.189661Copy

RELATED ARTICLES

Matched on section and article type within this issue of J Pharmacol. Pharmacother..

• Article · VOLUME 7, ISSUE 3Deprescription: The prescription metabolismGurusamy Sivagnanam · pp. 133–137Same type: Article
• Article · VOLUME 7, ISSUE 3Cold sodium chloride solution 0.9% and infrared thermography can be an alternative to radiopaque contrast agents in phlebographyAleksandr Livievich Urakov, Anton Aleksandrovic Kasatkin, Natalia Aleksandrovna Urakova, Tatiana Viktorovna Urakova · pp. 138–9Same type: Article
• Article · VOLUME 7, ISSUE 3Cisplatin resistance reversal by disulfiram and caffeineAshish R. Kadia, Gaurang B. Shah · pp. 139–141Same type: Article
• Article · VOLUME 7, ISSUE 3Oxcarbazepine-induced drug rash with eosinophilia and systemic symptoms syndrome presenting as exfoliative dermatitisMahimanjan Saha, Surajit Gorai, Vaswatee Madhab · pp. 142–5Same type: Article